Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes.
Aged
Animals
Blood Coagulation
Diabetes Mellitus, Type 2
/ complications
Down-Regulation
Endothelial Cells
/ metabolism
Female
Fibrin Fibrinogen Degradation Products
/ metabolism
Humans
Inflammation
/ etiology
Male
Mice, Knockout
MicroRNAs
/ genetics
Middle Aged
NF-kappa B
/ metabolism
PTEN Phosphohydrolase
/ metabolism
Signal Transduction
THP-1 Cells
Thromboplastin
/ genetics
Thrombosis
/ etiology
Vascular Cell Adhesion Molecule-1
/ metabolism
alpha Karyopherins
/ metabolism
Diabetes complications
Diabetes mellitus
Endothelial cells
Monocytes
NFκB
PTEN
Thrombosis
Tissue factor
Vascular homeostasis
microRNA
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
17 02 2020
17 02 2020
Historique:
received:
06
11
2019
accepted:
26
01
2020
entrez:
19
2
2020
pubmed:
19
2
2020
medline:
1
9
2020
Statut:
epublish
Résumé
Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF promotes factor (F) Xa generation resulting in a pro-thrombotic state and cardiovascular complications. MicroRNA (miR)s impact gene expression on the post-transcriptional level and contribute to vascular homeostasis. Their distinct role in the control of the diabetes-related procoagulant state remains poorly understood. In a cohort of patients with poorly controlled type 2 diabetes (n = 46) plasma levels of miR-181b were correlated with TF pathway activity and markers for vascular inflammation. In vitro, human microvascular endothelial cells (HMEC)-1 and human monocytes (THP-1) were transfected with miR-181b or anti-miR-181b and exposed to tumor necrosis factor (TNF) α or lipopolysaccharides (LPS). Expression of TF isoforms, vascular adhesion molecule (VCAM) 1 and nuclear factor (NF) κB nuclear translocation was assessed. Moreover, aortas, spleen, plasma, and bone marrow-derived macrophage (BMDM)s of mice carrying a deletion of the first miR-181b locus were analyzed with respect to TF expression and activity. In patients with type 2 diabetes, plasma miR-181b negatively correlated with the procoagulant state as evidenced by TF protein, TF activity, D-dimer levels as well as markers for vascular inflammation. In HMEC-1, miR-181b abrogated TNFα-induced expression of flTF, asTF, and VCAM1. These results were validated using the anti-miR-181b. Mechanistically, we confirmed a miR-181b-mediated inhibition of importin-α3 (KPNA4) leading to reduced nuclear translocation of the TF transcription factor NFκB. In THP-1, miR-181b reduced both TF isoforms and FXa generation in response to LPS due to targeting phosphatase and tensin homolog (PTEN), a principal inducer for TF in monocytes. Moreover, in miR-181-/- animals, we found that reduced levels of miR-181b were accompanied by increased TF, VCAM1, and KPNA4 expression in aortic tissue as well as increased TF and PTEN expression in spleen. Finally, BMDMs of miR-181-/- mice showed increased TF expression and FXa generation upon stimulation with LPS. miR-181b epigenetically controls the procoagulant state in diabetes. Reduced miR-181b levels contribute to increased thrombogenicity and may help to identify individuals at particular risk for thrombosis.
Sections du résumé
BACKGROUND
Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF promotes factor (F) Xa generation resulting in a pro-thrombotic state and cardiovascular complications. MicroRNA (miR)s impact gene expression on the post-transcriptional level and contribute to vascular homeostasis. Their distinct role in the control of the diabetes-related procoagulant state remains poorly understood.
METHODS
In a cohort of patients with poorly controlled type 2 diabetes (n = 46) plasma levels of miR-181b were correlated with TF pathway activity and markers for vascular inflammation. In vitro, human microvascular endothelial cells (HMEC)-1 and human monocytes (THP-1) were transfected with miR-181b or anti-miR-181b and exposed to tumor necrosis factor (TNF) α or lipopolysaccharides (LPS). Expression of TF isoforms, vascular adhesion molecule (VCAM) 1 and nuclear factor (NF) κB nuclear translocation was assessed. Moreover, aortas, spleen, plasma, and bone marrow-derived macrophage (BMDM)s of mice carrying a deletion of the first miR-181b locus were analyzed with respect to TF expression and activity.
RESULTS
In patients with type 2 diabetes, plasma miR-181b negatively correlated with the procoagulant state as evidenced by TF protein, TF activity, D-dimer levels as well as markers for vascular inflammation. In HMEC-1, miR-181b abrogated TNFα-induced expression of flTF, asTF, and VCAM1. These results were validated using the anti-miR-181b. Mechanistically, we confirmed a miR-181b-mediated inhibition of importin-α3 (KPNA4) leading to reduced nuclear translocation of the TF transcription factor NFκB. In THP-1, miR-181b reduced both TF isoforms and FXa generation in response to LPS due to targeting phosphatase and tensin homolog (PTEN), a principal inducer for TF in monocytes. Moreover, in miR-181-/- animals, we found that reduced levels of miR-181b were accompanied by increased TF, VCAM1, and KPNA4 expression in aortic tissue as well as increased TF and PTEN expression in spleen. Finally, BMDMs of miR-181-/- mice showed increased TF expression and FXa generation upon stimulation with LPS.
CONCLUSIONS
miR-181b epigenetically controls the procoagulant state in diabetes. Reduced miR-181b levels contribute to increased thrombogenicity and may help to identify individuals at particular risk for thrombosis.
Identifiants
pubmed: 32066445
doi: 10.1186/s12933-020-0993-z
pii: 10.1186/s12933-020-0993-z
pmc: PMC7027062
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
KPNA4 protein, human
0
MIRN-181 microRNA, human
0
MicroRNAs
0
NF-kappa B
0
Vascular Cell Adhesion Molecule-1
0
alpha Karyopherins
0
fibrin fragment D
0
importin alpha 3, mouse
0
mirn181 microRNA, mouse
0
Thromboplastin
9035-58-9
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Pten protein, mouse
EC 3.1.3.67
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Références
Blood. 2005 Jan 1;105(1):192-8
pubmed: 15339841
J Biol Chem. 2002 Aug 30;277(35):32124-32
pubmed: 12052830
Int J Mol Sci. 2017 Feb 28;18(3):
pubmed: 28264477
Nat Commun. 2015 Sep 02;6:8084
pubmed: 26330140
Blood. 2000 Jul 1;96(1):170-5
pubmed: 10891447
Eur Heart J. 2019 Oct 21;40(40):3318-3332
pubmed: 31004144
Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1263-71
pubmed: 27127202
Blood. 2015 May 14;125(20):3202-12
pubmed: 25838349
Oncotarget. 2017 Jun 16;8(57):96958-96969
pubmed: 29228585
Blood. 2010 Aug 5;116(5):806-14
pubmed: 20410508
Circ Res. 2016 May 27;118(11):1771-85
pubmed: 27230641
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7407-12
pubmed: 23589855
FASEB J. 2016 Sep;30(9):3216-26
pubmed: 27297585
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2839-43
pubmed: 2704749
Cardiovasc Diabetol. 2015 Feb 03;14:15
pubmed: 25645908
Circulation. 2003 Feb 25;107(7):973-7
pubmed: 12600909
Blood. 2018 May 10;131(19):2161-2172
pubmed: 29439952
Eur Heart J. 2017 Feb 14;38(7):511-515
pubmed: 28011706
Immunity. 2013 May 23;38(5):984-97
pubmed: 23623381
J Clin Invest. 2015 Apr;125(4):1471-84
pubmed: 25705884
Blood. 2004 Nov 15;104(10):3190-7
pubmed: 15280200
Thromb Res. 2016 Mar;139:90-7
pubmed: 26916302
Trends Cardiovasc Med. 2017 Feb;27(2):155-156
pubmed: 27769629
Circ Res. 2016 Mar 4;118(5):810-21
pubmed: 26830849
Circ J. 2015;79(11):2329-31
pubmed: 26447121
N Engl J Med. 2012 Jan 5;366(1):9-19
pubmed: 22077192
Circ Res. 2009 Mar 13;104(5):589-99
pubmed: 19168442
J Am Coll Cardiol. 2013 Nov 5;62(19):1737-45
pubmed: 23871888
Cardiovasc Diabetol. 2019 Aug 30;18(1):113
pubmed: 31470851
Trends Cardiovasc Med. 2016 May;26(4):297-303
pubmed: 26877187
Curr Pharm Des. 2016;22(4):472-84
pubmed: 26696253
J Immunol. 2008 Mar 15;180(6):4218-26
pubmed: 18322234
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1516-21
pubmed: 18227515
Thromb Res. 2010 Feb;125(2):112-8
pubmed: 19647294
Cardiovasc Diabetol. 2018 Mar 22;17(1):43
pubmed: 29566757
Heart. 2004 Mar;90(3):264-9
pubmed: 14966041
J Clin Invest. 2012 Jun;122(6):1973-90
pubmed: 22622040
Cardiovasc Diabetol. 2018 Feb 24;17(1):34
pubmed: 29477147
Circ Res. 2010 Sep 17;107(6):810-7
pubmed: 20651284
Circ Res. 2014 Jan 3;114(1):32-40
pubmed: 24084690
J Am Coll Cardiol. 2005 Apr 5;45(7):1081-9
pubmed: 15808768
Blood. 2012 Jul 19;120(3):636-46
pubmed: 22661702
Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13450-5
pubmed: 20624982
J Clin Invest. 2011 Jul;121(7):2932-44
pubmed: 21670495